Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-onsnews2026-07-30T19:22:42+00:00July 30th, 2026|Endpoints News|
Replimune scores win as FDA advisors back melanoma treatmentnews2026-07-30T19:11:21+00:00July 30th, 2026|Endpoints News|
First round of Trump’s 100% pharma tariffs won’t start Friday as plannednews2026-07-30T17:37:01+00:00July 30th, 2026|Endpoints News|
Trump’s CDC pick Erica Schwartz clears crucial vote in Senatenews2026-07-30T15:58:35+00:00July 30th, 2026|Endpoints News|
UCB’s stock slides despite Bimzelx revenue beating forecastsnews2026-07-30T15:24:12+00:00July 30th, 2026|Endpoints News|
Garijo’s plan to revamp Sanofi: an R&D cleanup, more M&A and a China pushnews2026-07-30T15:18:33+00:00July 30th, 2026|Endpoints News|
Pfizer’s Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182Mnews2026-07-30T15:16:51+00:00July 30th, 2026|Endpoints News|
AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly dealnews2026-07-30T15:10:46+00:00July 30th, 2026|Endpoints News|
Takeda, Regeneron, Sanofi and Bristol Myers trim pipelinesnews2026-07-30T15:02:43+00:00July 30th, 2026|Endpoints News|